# A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

Source: https://onco.cc/trials/nct05952037/  
OnCo record `nct05952037` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Sonrotoclax and Zanubrutinib in waldenström macroglobulinaemia, run by BeOne Medicines, active and no longer recruiting.

## Summary

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia is a phase 2 interventional study registered as NCT05952037 by BeOne Medicines, with 114 participants enrolled, started 2023-10-23 and due to reach its primary completion in 2026-09-22. Interventions recorded: Sonrotoclax and Zanubrutinib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05952037
- Phase: 2
- Setting: An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia
- Sponsor: BeOne Medicines
- Enrolled: 114

## Sources

- ClinicalTrials.gov NCT05952037: https://clinicaltrials.gov/study/NCT05952037

## Connected records

- cancers: [Waldenström macroglobulinaemia](https://onco.cc/cancers/waldenstrom/)
- drugs: [Sonrotoclax](https://onco.cc/drugs/sonrotoclax/), [Zanubrutinib](https://onco.cc/drugs/zanubrutinib/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)

---
JSON: https://onco.cc/api/v1/entities/nct05952037.json